Investment Thesis
Cabaletta Bio is a pre-revenue biotech company with severe cash burn and negative profitability metrics, losing $125.9M annually with an operating cash outflow of $95.7M. While the company maintains adequate liquidity with $60.2M in cash and a 3.60x current ratio, the burn rate at current levels suggests less than 18 months of runway without additional funding or operational changes. The absence of revenue combined with deteriorating unit economics (negative ROE of -90.3% and ROA of -66.4%) indicates the company remains in early clinical/development stages with substantial execution risk.
Strengths
- Adequate near-term liquidity with $60.2M cash and 3.60x current ratio providing runway for operations
- Conservative balance sheet with zero long-term debt and low leverage (0.00x debt/equity ratio)
- Significant shareholder equity base of $139.5M suggesting prior capital raises and investor backing
Risks
- Pre-revenue company with $125.9M net losses and $95.7M annual operating cash burn indicating unsustainable economics without clinical/commercial success
- Less than 18 months of cash runway at current burn rate, necessitating additional capital raise or dramatic operational improvements
- Early stage biotech with no revenue generation and uncertain path to profitability; high probability of total capital loss if pipeline assets fail in development
Key Metrics to Watch
- Operating cash burn rate and runway to profitability or next funding milestone
- Clinical trial progression and regulatory pathway status for lead candidates
- Quarterly cash position changes and any announcement of financing activities or partnerships
Financial Metrics
Revenue
N/A
Net Income
-125.9M
EPS (Diluted)
$-1.75
Free Cash Flow
-96.8M
Total Assets
189.8M
Cash
60.2M
Profitability Ratios
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
ROE
-90.3%
ROA
-66.4%
FCF Margin
N/A
Balance Sheet & Liquidity
Current Ratio
3.60x
Quick Ratio
3.60x
Debt/Equity
0.00x
Debt/Assets
26.5%
Interest Coverage
-89.46x
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-03-21T20:38:11.789818 |
Data as of: 2025-09-30 |
Powered by Claude AI